Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Ariel Fund declined -0.66% in the quarter, falling shy of Russell 2500 Value and Russell 2500 Indices, which returned -0.26% ...
21h
Hosted on MSNHexaware Technologies IPO debuts strongly on NSEHexaware Technologies debuted positively on the National Stock Exchange (NSE) on Wednesday, listing shares at a 5.3% premium ...
The Aiken County Historical Museum will continue its Winter Lecture Series at 3 p.m. Sunday, Feb. 23. The program will be The ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results